Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer. (1st October 2003)

• Record Type: Journal Article
• Authors: Piccart, M. J.; Bertelsen, K.; Stuart, G.; Cassidy, J.; Mangioni, C.; Simonsen, E.; James, K.; Kaye, S.; Vergote, I.; Blom, R.; Grimshaw, R.; Atkinson, R.; Swenerton, K.; Trope, C.; Nardi, M.; Kaern, J.; Tumolo, S.; Timmers, P.; Roy, J.-A.; Lhoas, F.; Lidvall, B.; Bacon, M.; Birt, A.; Andersen, J.; Zee, B.; Paul, J.; Pecorelli, S.; Baron, B.; Mcguire, W.
• Is Part Of: International journal of gynecological cancer. Volume 13(2003)Supplement 2
• Page Start: 144
• Page End: 148
• Publication Date: 2003-10-01
• Subjects: advanced stage -- chemotherapy -- cisplatin -- ovarian neoplasm -- paclitaxel; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-00009577-200311001-00003
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European–Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin–paclitaxel regimen over cisplatin–cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.